Ascendis Pharma (ASND) return on equity (ROE)

Return on equity · fiscal 2022
-221.5%

Only 1 fiscal year of return on equity is on record here for Ascendis Pharma (ASND); a history needs at least 3. Figures as of 17 Nov 2026, 20:47 UTC, from Yahoo Finance.

Key facts

Return on equity, fiscal 2022
-221.5%
Fiscal years on record
12022–2022

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Not enough data

A history of return on equity needs at least 3 fiscal years; one is on record here for Ascendis Pharma. Nothing is estimated to fill the gap. What is on record is in the table below.

Ascendis Pharma return on equity (ROE), year by year

Ascendis Pharma (ASND) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2022-221.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Ascendis Pharma and comparable companies
CompanyReturn on equityFiscal year
Revvity RVTY3.3%2025
Exelixis EXEL36.2%2025
Charles River Laboratories International CRL-4.6%2025
Neurocrine Biosciences NBIX14.7%2025
Ascendis Pharma ASND-221.5%2022
ICON ICLR2.5%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ASND

Ascendis Pharma, figure by figure

Ascendis Pharma (ASND) overview: price, valuation and scorecardAll health care companies by market value

Ascendis Pharma return on equity (ROE): questions and answers

How is Ascendis Pharma's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ascendis Pharma (ASND) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/ASND/roe

Underlying data: Yahoo Finance.